View up-to-date information on WuXi Biologics Cayman Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP4048697A1 | Application | NEUARTIGE ANTI-CD47-ANTIKÖRPER UND VERWENDUNGEN DAVON | A61K2039/505; A61K2039/507; A61P35/00; C07K16/2803; C07K16/286; C07K16/2863; C07K2317/21; C07K2317/24; C07K2317/33; C07K2317/52; C07K2317/73; C07K2317/732; C07K2317/734; C07K2317/76; C07K2317/90; C07K2317/92; C07K2317/94; G01N33/574 | August 31, 2022 |
| US20220267467A1 | Application | POLYPEPTIDE COMPLEX FOR CONJUGATION AND USE THEREOF | A61K47/6803; A61P35/00; C07K16/2863; C07K16/2887; C07K16/32; C07K2317/53; C07K2317/55 | August 25, 2022 |
| EP3874023A4 | Search Report | ZELLKULTURVERFAHREN DURCH VERSTÄRKTE PERFUSION MIT KONTINUIERLICHER ERNTE UND OHNE ZELLBLUTUNG | C07K16/00; C07K16/241; C07K16/2803; C07K16/2809; C07K2317/31; C12M29/10; C12M33/14; C12M47/10 | August 17, 2022 |
| EP3894442A4 | Search Report | ANTI-TIM-3-ANTIKÖRPER UND VERWENDUNGEN DAVON | A61K2039/505; A61P35/00; A61P37/02; C07K16/2803; C07K2317/21; C07K2317/33; C07K2317/40; C07K2317/56; C07K2317/565; C07K2317/75; C07K2317/76; C07K2317/92; C12N5/12 | August 10, 2022 |
| EP4034569A1 | Application | NEUARTIGER ANTI-PD-L1/ANTI-LAG-3 BISPEZIFISCHER ANTIKÖRPER UND VERWENDUNGEN DAVON | A61K2039/505; A61P31/00; A61P35/00; A61P37/00; C07K16/2803; C07K16/2827; C07K2317/14; C07K2317/22; C07K2317/24; C07K2317/31; C07K2317/33; C07K2317/56; C07K2317/565; C07K2317/569; C07K2317/64; C07K2317/73; C07K2317/76; C07K2317/90; C07K2317/92; C07K2317/94; C12N15/85; C12N2800/107; G01N33/68 | August 03, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer